The Source Blog
Recent Action in Pharmaceuticals
SB875 – Virginia
Introduced: 2025 Status: In Process
This bill requires the Department of Medical Assistance Services (DMAS) to select and contract with a third-party administrator to serve as the state pharmacy benefits manager (PBM) by December 31, 2025, who will administer pharmacy […]
SB1359 – Virginia
Introduced: 2025 Status: In Process
This bill amends Virginia law to strengthen regulations governing health carriers and pharmacy benefits managers (PBMs), which are third-party administrators that manage prescription drug benefits for health insurance plans. The bill prohibits several unfair practices, […]
SB1078 – Virginia
Introduced: 2025 Status: In Process
This bill addresses several key provisions related to health insurance, pharmacy benefits managers (PBMs), and prescription drug cost-sharing. It requires that when calculating an enrollee’s out-of-pocket costs for prescription drugs at the point of sale, […]
HB1724 – Virginia
Introduced: 2025 Status: In Process
This bill establishes a Prescription Drug Affordability Board (the Board) in Virginia to address high prescription drug costs, with the goal of protecting citizens and healthcare stakeholders. The Board will consist of five nonlegislative citizen […]
S03203 – New York
Introduced: 2025 Status: In Process
This bill aims to preserve access to affordable drugs by establishing new regulations for patent settlements between brand-name drug companies and generic or biosimilar drug manufacturers. Specifically, the bill creates a legal presumption that certain […]
A01720 – New York
Introduced: 2025 Status: In Process
This bill establishes patient safety and quality assurance measures for medication distribution by insurers, specifically addressing “brown bagging” and “white bagging” practices. Brown bagging occurs when patients are required to transport medications from a designated […]
SB0503 – Indiana
Introduced: 2025 Status: In Process
This bill establishes a comprehensive framework for managing pharmacy benefit administration in Indiana, focusing on prescription drug benefits for state employee health plans and the Medicaid program. The legislation creates a new Pharmacy Benefit Compliance […]
Next | See all Legislation Records
Introduced: 2025 Status: In Process
This bill requires the Department of Medical Assistance Services (DMAS) to select and contract with a third-party administrator to serve as the state pharmacy benefits manager (PBM) by December 31, 2025, who will administer pharmacy […]
SB1359 – Virginia
Introduced: 2025 Status: In Process
This bill amends Virginia law to strengthen regulations governing health carriers and pharmacy benefits managers (PBMs), which are third-party administrators that manage prescription drug benefits for health insurance plans. The bill prohibits several unfair practices, […]
SB1078 – Virginia
Introduced: 2025 Status: In Process
This bill addresses several key provisions related to health insurance, pharmacy benefits managers (PBMs), and prescription drug cost-sharing. It requires that when calculating an enrollee’s out-of-pocket costs for prescription drugs at the point of sale, […]
HB1724 – Virginia
Introduced: 2025 Status: In Process
This bill establishes a Prescription Drug Affordability Board (the Board) in Virginia to address high prescription drug costs, with the goal of protecting citizens and healthcare stakeholders. The Board will consist of five nonlegislative citizen […]
S03203 – New York
Introduced: 2025 Status: In Process
This bill aims to preserve access to affordable drugs by establishing new regulations for patent settlements between brand-name drug companies and generic or biosimilar drug manufacturers. Specifically, the bill creates a legal presumption that certain […]
A01720 – New York
Introduced: 2025 Status: In Process
This bill establishes patient safety and quality assurance measures for medication distribution by insurers, specifically addressing “brown bagging” and “white bagging” practices. Brown bagging occurs when patients are required to transport medications from a designated […]
SB0503 – Indiana
Introduced: 2025 Status: In Process
This bill establishes a comprehensive framework for managing pharmacy benefit administration in Indiana, focusing on prescription drug benefits for state employee health plans and the Medicaid program. The legislation creates a new Pharmacy Benefit Compliance […]
Next | See all Legislation Records
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in […]
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of […]
In re: Flonase Antitrust Litigation – Louisiana, Pennsylvania
District Court: Eastern District of Pennsylvania Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline […]
Mohr-Lercara v. Oxford Health Ins., Inc. – New York
District Court: Southern District of New York Status: Pending
A proposed class action was filed in New York federal court accusing Oxford Health Insurance of overcharging patients for prescription drugs. The complaint alleges that […]
In Re UnitedHealth Group PBM Litigation – Minnesota
District Court: District of Minnesota Status: Decided
Plan members brought suit against UnitedHealth Group, Inc. under ERISA and RICO for Defendants’ conduct in administrating pharmacy benefits that allegedly caused Plaintiffs to overpay […]
Negron v. Cigna and OptumRx – Connecticut
District Court: District of Connecticut Status: Pending
Cigna faces a class-action lawsuit alleging the insurance giant overcharged its members by more than 10 times the amount the insurer paid for certain prescription […]
Federal Trade Commission v. Actavis, Inc. – Georgia
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims […]
Previous | Next | See all Litigation Records
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in […]
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of […]
In re: Flonase Antitrust Litigation – Louisiana, Pennsylvania
District Court: Eastern District of Pennsylvania Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline […]
Mohr-Lercara v. Oxford Health Ins., Inc. – New York
District Court: Southern District of New York Status: Pending
A proposed class action was filed in New York federal court accusing Oxford Health Insurance of overcharging patients for prescription drugs. The complaint alleges that […]
In Re UnitedHealth Group PBM Litigation – Minnesota
District Court: District of Minnesota Status: Decided
Plan members brought suit against UnitedHealth Group, Inc. under ERISA and RICO for Defendants’ conduct in administrating pharmacy benefits that allegedly caused Plaintiffs to overpay […]
Negron v. Cigna and OptumRx – Connecticut
District Court: District of Connecticut Status: Pending
Cigna faces a class-action lawsuit alleging the insurance giant overcharged its members by more than 10 times the amount the insurer paid for certain prescription […]
Federal Trade Commission v. Actavis, Inc. – Georgia
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims […]
Previous | Next | See all Litigation Records
News & Opinions
Articles & Reports
Health Affairs Forefront
January 14, 2025
Value in Health Journal December 1, 2024
Health Affairs December 1, 2024
Health Affairs Forefront October 10, 2024
Value in Health Journal December 1, 2024
Health Affairs December 1, 2024
Health Affairs Forefront October 10, 2024
Trends in Pharmaceuticals
2019 Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Price Transparency
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Rate Setting
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Price Gouging
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Drug Importation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Pharmacy Gag Clause Regulation
Gag clause regulation includes laws that allow pharmacists to disclose costs to insured patients and those that prohibit pharmacists from collecting more in cost-sharing from the insured patient than the cash price. See The Source’s Spotlight on 2018 State Drug Legislation Part 3 and 2018 legislation chart for more information.
-
Key:
- Enacted
- Considered
- No Legislative Session
PBM Regulation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Pharma Other
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session